Proprietary Radio DARPin Therapy Platform designed to deliver high amount of radioactivity to the tumor while maintaining low accumulation in other tissues
Data reveal engineering approach to significantly reduce kidney accumulation of DARPin-based radiotherapeutic candidates to potentially expand therapeutic window of the class
Several in-house and Novartis-partnered DARPin-based radiotherapeutic programs in indications with high unmet medical need currently underway
Data to be presented at the 12th International Symposium on Targeted Alpha Therapy (TAT 12)
ZURICH-SCHLIEREN, Switzerland and CONCORD, MA, USA I February 28, 2023 I
Molecular Partners AG
(SIX: MOLN; NASDAQ: MOLN), a clinical-stage biotech company developing a new class of custom-built protein drugs known as DARPin therapeutics, today announced the presentation of new preclinical data from the company’s Radio DARPin Therapy Platform at the 12
th
International Symposium on Targeted Alpha Therapy (TAT 12) in Cape Town, South Africa on February 28, 2023. The platform represents a unique and innovative delivery system for radioactive payloads to solid tumors, an approach with proven potential but with technological limitations that DARPins may address.
“These initial data demonstrate the potential of our approach to deliver high amounts of radioactivity to the tumor while overcoming the challenge of small, protein-based delivery vectors accumulating in the kidney. The therapeutic opportunity emerging from this approach is to enhance both safety and efficacy as higher dosages of radioactivity will selectively accumulate at the tumor site,” said Daniel Steiner, Ph.D., Senior Vice President of Research at Molecular Partners. “Following our recent selection of DLL3 as the first disclosed target and the progression of several other discovery-stage programs underway, both in-house and with our partner Novartis, we look forward to continuing to expand the technological capabilities of our Radio DARPin Therapy Platform.”
The presented data demonstrate Molecular Partners’ ability to engineer the surface of DARPin-based radiotherapeutics to dramatically reduce its accumulation in the kidney, a historical challenge with small protein-based delivery vectors. In preclinical models, the surface engineering did not affect tumor uptake or uptake in other healthy organs and combination with another kidney reduction strategy provided a cumulative benefit.
These results will be presented at TAT12 in a poster, the details of which can be found below. The poster will be made available on Molecular Partners website, after the presentation.
Poster:
“DARPins as Powerful Targeting Agents for Radioligand Therapeutics”
Number:
33
Timing:
February 28, 2023
Presenter:
Daniel Steiner, Ph.D., Senior Vice President of Oncology Research
About Molecular Partners AG
Molecular Partners AG is a clinical-stage biotech company developing DARPin therapeutics, a new class of custom-built protein drugs designed to address challenges current modalities cannot. The Company has formed partnerships with leading pharmaceutical companies to advance DARPin therapeutics in the areas of oncology and infectious disease and has compounds in various stages of clinical and preclinical development across multiple therapeutic areas.
www.molecularpartners.com
; Find us on Twitter -
@MolecularPrtnrs
SOURCE:
Molecular Partners
